Enterprise Value

1.522B

Cash

372.4M

Avg Qtr Burn

N/A

Short % of Float

19.40%

Insider Ownership

19.77%

Institutional Own.

91.79%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
WAKIX® (pitolisant) Details
Excessive daytime sleepiness, Genetic disorder, Cataplexy, Narcolepsy, Prader-Willi syndrome

Approved

Quarterly sales

PDUFA

Approval decision

WAKIX® (pitolisant) Details
EDS in Idiopathic Hypersomnia

sNDA

Submission

WAKIX® (pitolisant) Details
Rare genetic disease, Genetic disorder, Prader-Willi syndrome, Excessive daytime sleepiness

Phase 3

Data readout

Zygel (ZYN002 CBD Gel) Details
Rare genetic disease, Genetic disorder, Fragile X syndrome

Phase 3

Data readout

Zygel (ZYN002 CBD Gel) Details
Rare genetic disease, Genetic disorder, Deletion Syndrome , 22q11.2 deletion syndrome

Phase 3

Initiation

Phase 2

Data readout

WAKIX® (pitolisant) Details
Muscle weakness, Muscle degeneration, Myotonic Dystrophy Type 1

Phase 2

Update

TPM-1116 [orexin-2 receptor agonist] Details
Narcolepsy, Sleep-wake disorder

IND

Submission